Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206102 · ClinicalTrials.gov registry record · Phase 4
A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,098
- Enrollment target
NCT00206102: Completed Phase 4 study, sponsored by AstraZeneca.
NCT00206102 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 1,098 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (112% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00206102, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,098 participants
- Enrollment target
Study Summary
This Phase IV, randomized, parallel-group study is designed to evaluate the cataractogenic potential of quetiapine fumarate (SEROQUEL) compared with that of a putative non-cataractogenic antipsychotic medication risperidone (RISPERDAL). This study is being conducted to fulfill the SEROQUEL Phase IV commitment regarding evaluation of cataractogenic potential.
Primary Outcome
Presence of C type of cataractogenic potential event in participant was defined if any LOCS II grades of 2, 3, 4, 5 (with any grade of 0, trace,1 at randomization) assessed and agreed by 2 independent, treatment-masked ophthalmologists at any post-randomization assessment in one or both eyes. 0= no cataract; 5 is worst. There are no subscales. 0 is the best, 5 is the worst.
Interventions
- DRUG risperidone
- DRUG quetiapine fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,098 participants |
| Start Date | 2003-09 |
| Est. Completion | 2008-10 |
| Phase | Phase 4 |
What the finished NCT00206102 record still lists
NCT00206102 is an interventional study that assigns participants to a tested intervention. Its 1,098 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (112% higher).
The record links to 0 conditions, and to 2 interventions - of which risperidone is the first listed.
NCT00206102 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00206102 about?
NCT00206102 is a clinical study titled "A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder". This Phase IV, randomized, parallel-group study is designed to evaluate the cataractogenic potential of quetiapine fumarate (SEROQUEL) compared with that of a putative non-cataractogenic antipsychotic medication risperidone (RISPERDAL). This study is being conducted to fulfill the SEROQUEL Phase IV ...
What is the current status of trial NCT00206102?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,098 participants. The study started on 2003-09. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00206102?
The interventions under investigation include: risperidone (DRUG), quetiapine fumarate (DRUG).
Who is sponsoring clinical trial NCT00206102?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00206102's enrollment target sits among peer trials
1,098 65th of 2000 higher than 1,936 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00710112 · 1,100 participants
Genetic Variants and Susceptibility to Diseases of Prematurity in Very Low Birth-Weight Infants
- NCT02688517 · 1,100 participants
Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer
- NCT04743765 · 1,100 participants · NA
HIP Fracture Accelerated Surgical TreaTment And Care tracK 2 Trial
- NCT05638581 · 1,100 participants · Phase 3
Trauma Resuscitation With Low-Titer Group O Whole Blood or Products
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia